An Exploratory, Phase II Trial to Determine the Association of Lapatinib-Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer

Trial Profile

An Exploratory, Phase II Trial to Determine the Association of Lapatinib-Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 May 2013 Planned end date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top